The Authority seeks to establish a Framework Agreement covering Multiple Sclerosis medicines. The range of medicines under consideration for inclusion in the Framework Agreement are listed below (subject to removal or replacement due to a continually shifting litigation landscape): Glatiramer acetate Interferon beta-1a Teriflunomide Dimethyl fumarate Fingolimod Natalizumab Cladribine

Glatiramer acetate, Interferon beta-1a and Natalizumab

Supply of Glatiramer acetate, Interferon beta-1a and Natalizumab to NHS Scotland. The Authority intends to award this Lot as an unranked multi supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Fingolimod, Teriflunomide and Dimethyl Fumarate

Supply of Fingolimod, Teriflunomide and Dimethyl Fumarate to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.

Cladribine tablets

Supply of cladribine tablets to NHS Scotland. The Authority intends to award this Lot as a ranked multi-supplier Framework Agreement per product line. Full details of Goods and volumes will be found within the ITT documents once published.